Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Endovia Health Sciences, Inc.SBEV · Entity 8508 | Chief Financial Officer | May 02, 2023 | August 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Endovia Health Sciences, Inc.
Report date May 02, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2033-05-02 | Direct | 333,000 |
Reported balance
After 2023-05-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-02 · Grant · Acquired 222,000 · Balance 333,000 F1: The options are being issued in connection with serving as the chief financial officer of SBEV, pursuant to the 2020 Long-Term Incentive Compensation Plan. 166,500 of the options vested on May 2, 2023 and 55,500 options will vest on May 2, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are being issued in connection with serving as the chief financial officer of SBEV, pursuant to the 2020 Long-Term Incentive Compensation Plan. 166,500 of the options vested on May 2, 2023 and 55,500 options will vest on May 2, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2023 Filed Aug 3, 2023 17:41 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantStock options · Derivative | 222,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001731122-23-001343 · ownership.xml · derivative · entry 1 Wall Ronald Charles · CIK 0001925305 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,000 Underlying: Common stock · 222,000 shares Expires 2033-05-02 F1 · derivative.exercise_date: The options are being issued in connection with serving as the chief financial officer of SBEV, pursuant to the 2020 Long-Term Incentive Compensation Plan. 166,500 of the options vested on May 2, 2023 and 55,500 options will vest on May 2, 2024. Read SEC document |
| May 02, 2022 Filed Jan 31, 2023 20:18 UTC | Endovia Health Sciences, Inc. SBEV · Entity 8508 | GrantOption (Right to Buy) · Derivative | 111,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001731122-23-000105 · ownership.xml · derivative · entry 1 Wall Ronald Charles · CIK 0001925305 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires 2032-05-02 F1 · derivative.exercise_date: One-fourth of the Options vested on May 2, 2022. One-fourth of the Options will vest on May 2, 2023, May 2, 2024, and May 2, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.